22:14 , Jul 29, 2019 |  BC Extra  |  Company News

July 29 Management tracks: Verastem names CEO; plus Zealand, Turning Point, Arvinas and more

Verastem Inc. (NASDAQ:VSTM) named board member Brian Stuglik as CEO. In June, Robert Forrester stepped down as the cancer company's president and CEO; COO Dan Paterson succeeded Forrester as president and led the executive team...
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
01:49 , Feb 8, 2019 |  BC Week In Review  |  Clinical News

CTI withdraws MAA for myleofibrosis therapy

CTI BioPharma Corp. (NASDAQ:CTIC) withdrew its MAA for pacritinib to treat myelofibrosis following interactions with EMA's CHMP suggesting the committee was likely to issue a negative opinion. CTI said CHMP indicated the risk-benefit profile of...
19:29 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

CTI's Pixuvri fails in postapproval trial

CTI BioPharma Corp. (NASDAQ:CTIC) said Pixuvri pixantrone missed the primary endpoint in the postmarketing Phase III PIX306 trial to treat aggressive B-cell non-Hodgkin's lymphoma (NHL). The failure means PIX306 "has not met the specific obligations"...
16:53 , Jul 9, 2018 |  BC Extra  |  Clinical News

CTI's Pixuvri fails in postapproval trial

CTI BioPharma Corp. (NASDAQ:CTIC) said Pixuvri pixantrone missed the primary endpoint in the postmarketing Phase III PIX306 trial to treat aggressive B-cell non-Hodgkin's lymphoma (NHL). The failure means PIX306 "has not met the specific obligations"...
13:38 , Jun 26, 2018 |  BC Extra  |  Company News

No right-to-try for BrainStorm's ALS therapy

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) will not make its NurOwn therapy available under the U.S. right-to-try law, it announced Tuesday. NurOwn is in a Phase III trial to treat amyotrophic lateral sclerosis. It consists of...
21:00 , Jun 7, 2018 |  BC Extra  |  Company News

BrainStorm considering right to try for ALS therapy

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) is considering offering NurOwn to treat amyotrophic lateral sclerosis under the recently enacted federal right-to-try law, BrainStorm President and CEO Chaim Lebovits told BioCentury. He also discussed the company’s plans...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
19:35 , Feb 16, 2018 |  BC Week In Review  |  Financial News

CTI BioPharma prices $69M follow-on

Cancer company CTI BioPharma Corp. (NASDAQ:CTIC) raised $69 million through the sale of 20 million shares at $3 in a follow-on underwritten by Leerink Partners, JMP Securities, Needham and Oppenheimer. The figures includes a 3...
20:18 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

EMA grants CTI extension to respond to Day 120 questions for pacritinib

CTI BioPharma Corp. (NASDAQ:CTIC) said EMA's CHMP granted it a three month extension to submit responses to a Day 120 list of questions regarding its MAA for pacritinib (BAX 2201, ONX 0803, SB1518) to treat...